Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitybelle is a combined oral contraceptive (COC) containing the synthetic progestogen chlormadinone acetate and the synthetic estrogen ethinylestradiol. It is primarily indicated for the prevention of pregnancy and is also frequently prescribed for the treatment of moderate acne in women who require hormonal contraception. The mechanism of action involves the suppression of gonadotropin secretion from the pituitary gland, which inhibits ovulation, increases the viscosity of cervical mucus to impede sperm transport, and alters the endometrial lining to prevent implantation. Chlormadinone acetate is a derivative of progesterone that possesses significant anti-androgenic properties, allowing it to compete with endogenous androgens at the receptor level, thereby reducing sebum production and improving androgen-dependent skin conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vitybelle.